menu
    • menu
    [{"orgOrder":0,"company":"Undisclosed","sponsor":"MOMA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"MOMA-989","moa":"PARP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Undisclosed \/ MOMA Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Undisclosed \/ MOMA Therapeutics"},{"orgOrder":0,"company":"Tasca Therapeutics","sponsor":"Regeneron Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"CAS 77168-63-9","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tasca Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tasca Therapeutics \/ Regeneron Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Tasca Therapeutics \/ Regeneron Ventures"},{"orgOrder":0,"company":"Hervolution Therapeutics","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"IPT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hervolution Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Hervolution Therapeutics \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"Hervolution Therapeutics \/ Serum Institute of India"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BA1105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cartherics","sponsor":"Shunxi Holding Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CTH-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Shunxi Holding Group","highestDevelopmentStatusID":"5","companyTruncated":"Cartherics \/ Shunxi Holding Group"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Tenmile"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM 2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chimeric Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chimeric Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RAD204","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"Sar-Bombesin","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"AMP01","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Reverb Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Reverb Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian angel investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian angel investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Pharmaceuticals \/ Canadian angel investors"},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"MT-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Myeloid Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Acuitas \/ Myeloid Therapeutics"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"Polymerase Theta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"NTSR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac FPI-2068","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Defence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AccuTOX","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Defence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Defence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Defence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bria-Pros+","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"||NMDA 2B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"Nrf2\/Keap1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"Nrf2\/Keap1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW191","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Medicilon","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medicilon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicilon \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medicilon \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"IBI3009","moa":"DLL3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Duality Biologics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Tarlatamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"VelaVigo","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Nectin4\/TROP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"VelaVigo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VelaVigo \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VelaVigo \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"GQ1007","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ BrighGene Biomedical","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ BrighGene Biomedical"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Chipscreen NewWay Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"YH008","moa":"CTL4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Chipscreen NewWay Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Eucure Biopharma \/ Chipscreen NewWay Biosciences"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Full-Life Technologies \/ Focus-X Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Focus-X Therapeutics"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Sequoia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Fibroblast protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Full-Life Technologies \/ Sequoia","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Sequoia"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"||ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Dx","highestDevelopmentStatusID":"5","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Dx"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"A-337","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianweiyuanhe Biomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tianweiyuanhe Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC60","moa":"Fatty acid synthase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BC2027","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BC3448","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BR105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BRY812","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CD-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CD (Suzhou) Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CD (Suzhou) Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"WGc-043","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiauranib","moa":"||VEGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CS231295","moa":"Protein kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Fapon Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"FP002","moa":"CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fapon Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"GQ1001","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"GQ1005","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Genhouse Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HBI-2376","moa":"SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Genhouse Bio","highestDevelopmentStatusID":"5","companyTruncated":"HUYA Bioscience International \/ Genhouse Bio"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"SunHo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"IAP0971","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"SunHo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SunHo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SunHo \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Bcl-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-490","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunofoco \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunofoco \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JAB-30300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VS-7375","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LK101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Likang Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Likang Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Likang Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Neuboron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neuboron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuboron \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuboron \/ Inapplicable"},{"orgOrder":0,"company":"NK CellTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NK010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NK CellTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NK CellTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NK CellTech \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biopharma \/ MorphoSys"},{"orgOrder":0,"company":"HJB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HJB \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dragon Boat Pharmaceutical","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BC008","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dragon Boat Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals"},{"orgOrder":0,"company":"Qure Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qure Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qure Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qure Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SYS6020","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"JS006","moa":"||CD112R","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RD118","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onatasertib","moa":"||TORC1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Merck & Co"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"WGc-043","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JS110","moa":"XPO1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS03","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BR111","moa":"ROR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fapon Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"FP-008","moa":"PD-1\/IL-10M","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fapon Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biotech \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAE120","moa":"USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MRANK-106","moa":"WEE1\/YES1 kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"InProTher","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"IPT001","moa":"HERVs","graph1":"Oncology","graph2":"IND Enabling","graph3":"InProTher","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InProTher \/ European Innovation Council","highestDevelopmentStatusID":"5","companyTruncated":"InProTher \/ European Innovation Council"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADCE-D01","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TransCon IL-2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TransCon IL-2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"BioVaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"BioVaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys"},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"RCT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roca Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ 3B Future Health Fund II"},{"orgOrder":0,"company":"HEPHAISTOS-Pharma","sponsor":"Xista Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Onco-Boost","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HEPHAISTOS-Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"HEPHAISTOS-Pharma \/ Xista Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"HEPHAISTOS-Pharma \/ Xista Science Ventures"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"BioVaxys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GEORGIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belapectin","moa":"||Galectin-3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"||MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Asher Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProBioGen \/ Asher Bio","highestDevelopmentStatusID":"5","companyTruncated":"ProBioGen \/ Asher Bio"},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Roivant Sciences"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Athos Service","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"IMT-07","moa":"SIK3 kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Athos Service","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Athos Service"},{"orgOrder":0,"company":"Abalos","sponsor":"Seventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abalos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abalos \/ Seventure Partners","highestDevelopmentStatusID":"5","companyTruncated":"Abalos \/ Seventure Partners"},{"orgOrder":0,"company":"Merck Group","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Merck Group \/ Immutep","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Immutep"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Cell BioEngines"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Syena"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ I-Mab Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab Biopharma"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iOmx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TK-2504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Therapeutics \/ PharmaEssentia"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ISM3091","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Exelixis"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ISM025","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XL114","moa":"BTK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GRC 54276","moa":"HPK1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"sigx1094","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Funding","leadProduct":"Azacytidine","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Cancer Focus Fund","highestDevelopmentStatusID":"5","companyTruncated":"Kahr Medical \/ Cancer Focus Fund"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genenta Science \/ Ospedale San Raffaele","highestDevelopmentStatusID":"5","companyTruncated":"Genenta Science \/ Ospedale San Raffaele"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chordia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Chordia Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PD-29875","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"GEDiCube","sponsor":"Renovaro Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GEDiCube","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GEDiCube \/ Renovaro Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"GEDiCube \/ Renovaro Biosciences"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Gadeta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GDT002","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gadeta \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gadeta \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Apricoxib","moa":"||KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"},{"orgOrder":0,"company":"Engine Biosciences","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"ENB-812","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Engine Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engine Biosciences \/ Polaris Partners","highestDevelopmentStatusID":"5","companyTruncated":"Engine Biosciences \/ Polaris Partners"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRL03","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SCG142","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCG Cell Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SCG Cell Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Axcynsis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AT03-65","moa":"CLDN6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axcynsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcynsis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Axcynsis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ Kineta"},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Stassets Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"AD1208","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avelos Therapeutics \/ Stassets Investment","highestDevelopmentStatusID":"5","companyTruncated":"Avelos Therapeutics \/ Stassets Investment"},{"orgOrder":0,"company":"Peptron","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"PAb001-ADC","moa":"MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Peptron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptron \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Peptron \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SLC-3010","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"Selecxine \/ GenScript ProBio"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ National OncoVenture"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eutilex Inc \/ Samsung Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Eutilex Inc \/ Samsung Biologics"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX22","moa":"||HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Anocca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ANOC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anocca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anocca \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OPD5","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Neogap","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogap","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogap \/ Karolinska University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Neogap \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Medivir","sponsor":"Tango Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"USP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medivir \/ Tango Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medivir \/ Tango Therapeutics"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ RA Capital","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ RA Capital"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD25","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"CDR Life","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Series A Financing","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Jeito Capital"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Series D Financing","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Lonza Group","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ aTyr Pharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Leucid Bio"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ 3SBio","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3SBio"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANV600","moa":"||PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"GCX","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gnubiotics Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gnubiotics Sciences \/ University of Zurich","highestDevelopmentStatusID":"5","companyTruncated":"Gnubiotics Sciences \/ University of Zurich"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"OnTargetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ OnTargetx","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ OnTargetx"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"IDE397","moa":"||MAT2A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Amivantamab","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affini-T Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ ElevateBio"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Omega Funds"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"OneThree Biotech","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OneThree Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OneThree Biotech \/ Jubilant Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OneThree Biotech \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Atreca","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"ATRC-301","moa":"Ephrin type A receptor 2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Zymeworks","highestDevelopmentStatusID":"5","companyTruncated":"Atreca \/ Zymeworks"},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PMI21","moa":"PSMA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionetix \/ Precision Molecular","highestDevelopmentStatusID":"5","companyTruncated":"Ionetix \/ Precision Molecular"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ BridgeBio Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BITT","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"||TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ BeiGene"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx Inc"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Editas Medicine \/ Immatics","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Immatics"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Aleta Biotherapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Allomek","sponsor":"Camac Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"CIP-137401","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Camac Partners","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Camac Partners"},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"CO-sTiRNA","moa":"||STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scopus Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scopus Biopharma \/ The Benchmark Company","highestDevelopmentStatusID":"5","companyTruncated":"Scopus Biopharma \/ The Benchmark Company"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Link Immunotherapeutics","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CT-95","moa":"MSLN\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Link Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Link Immunotherapeutics \/ Context Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Link Immunotherapeutics \/ Context Therapeutics"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Cancer Research UK"},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"GPR132","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown University \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Brookline Capital Markets"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Cytovance Biologics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Cytovance Biologics"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Mirae Asset Financial Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series D Financing","leadProduct":"HFB200301","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Jefferies","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Jefferies"},{"orgOrder":0,"company":"Curia","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curia \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Curia \/ BryoLogyx Inc"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"Mesothelin protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"ROS1 selective kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/ Deerfield Management"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"Alterome Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fusion \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Kineta","sponsor":"Cheongbo Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Cheongbo Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Cheongbo Industrial"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ BlackRock"},{"orgOrder":0,"company":"GX Acquisition","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"CYNK-101","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"GX Acquisition","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GX Acquisition \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"GX Acquisition \/ Celularity"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ United States Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Plus Therapeutics \/ United States Department of Defense"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"The University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Public Offering","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ The University of Chicago","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ The University of Chicago"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Arix Bioscience Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Arix Bioscience Plc","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Arix Bioscience Plc"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Hande Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Hande Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Hande Sciences"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Res Nova Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Demerger","leadProduct":"ValloVax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Res Nova Bio","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Res Nova Bio"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ CIRM","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ CIRM"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sutro Biopharma \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Sutro Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"SNAPvax CV","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Avidea Technologies \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avidea Technologies \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Salinomycin","moa":"||Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Sapien Biosciences"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"Anocca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Emendo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emendo Biotherapeutics \/ Anocca","highestDevelopmentStatusID":"5","companyTruncated":"Emendo Biotherapeutics \/ Anocca"},{"orgOrder":0,"company":"Nusano","sponsor":"Starget Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"DOTA-PTR-58","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Starget Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Nusano \/ Starget Pharma"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"BITT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ BITT","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopharma \/ BITT"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MDM2 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Michigan \/ Ascentage Pharma","highestDevelopmentStatusID":"5","companyTruncated":"University of Michigan \/ Ascentage Pharma"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"FibroGen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Cemiplimab","moa":"||Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Editas Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Flare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Caris Life Sciences \/ Flare Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"Tempus","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"AVA6103","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempus \/ Avacta Group","highestDevelopmentStatusID":"5","companyTruncated":"Tempus \/ Avacta Group"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ NiKang Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ NiKang Therapeutics"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Kivu Bioscience","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"KIVU-107","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kivu Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kivu Bioscience \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"Kivu Bioscience \/ Organovo Holdings"},{"orgOrder":0,"company":"Georgiamune","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"GIM-122","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ General Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"Georgiamune \/ General Catalyst"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Cullgen","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"CG001419","moa":"TRK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ 3E Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ 3E Bioventures"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Akamis Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"NG-641","moa":"||AP\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Bristol Myers Squibb \/ Akamis Bio","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Akamis Bio"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"CTT2274","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"City of Hope \/ Scopus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Scopus Biopharma"},{"orgOrder":0,"company":"Puerto Rico Science Technology and Research Trust","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Puerto Rico Science Technology and Research Trust","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LTZ-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"IMM20320","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ATX-968","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"HDT-521","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HDT Biotech \/ BARDA","highestDevelopmentStatusID":"5","companyTruncated":"HDT Biotech \/ BARDA"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Affini-T Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Metagenomi \/ Affini-T Therapeutics"},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Columbia University \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"LTZ-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"OPB-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Outpace Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Outpace Bio \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Outpace Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ Labcorp","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Labcorp"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"225-Ac","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Pfizer Inc"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"OKI-219","moa":"PI3K Alpha H1047R","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Maxim Group LLC"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"UB-TT170","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ SoftBank Vision","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ SoftBank Vision"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ TILT Biotherapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"XinThera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"XIN5104","moa":"PARP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"XinThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XinThera \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"XinThera \/ Gilead Sciences"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"ImmunityBio \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Serum Institute of India"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ NMDP BioTherapies"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"||NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Medigene"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"TC-220","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Sawyer Corporation \/ TAE Life Sciences"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ University of California San Diego"},{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Clinical \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"XBIO-015","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"5","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Celcuity \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/ Pfizer Inc"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"HFB200603","moa":"||BLTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Shoreline Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Editas Medicine \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Shoreline Biosciences"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"Tissue Factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ Adcendo","highestDevelopmentStatusID":"5","companyTruncated":"Multitude Therapeutics \/ Adcendo"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Yumanity Therapeutics \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Yumanity Therapeutics \/ Kineta"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Veltmeyer MD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"ValloVax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Veltmeyer MD","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Veltmeyer MD"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affini-T Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Vida Ventures"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zumutor Biologics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"68-Ga FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofie Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sofie Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB-201","moa":"CD16","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB821","moa":"IL-21","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Focal Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focal Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Focal Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Focal Medical \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affini-T Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allomek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CIP-137401","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Inapplicable"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APR-548","moa":"p53","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Karolinska Development AB"},{"orgOrder":0,"company":"Adaptin Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"APTN-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptin Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptin Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adaptin Bio \/ Inapplicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ASP1012","moa":"Leptin-IL2 fusion protein expression","graph1":"Oncology","graph2":"IND Enabling","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA3271","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATV-1601","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atavistik Bio \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AUTX-703","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avstera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVS100","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avstera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avstera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avstera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BA3182","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BA3361","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"Virtuoso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD38\/ICAM-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Virtuoso Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtuoso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virtuoso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BITT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BITT-2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLEX 404","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABVC BioPharma \/ BIOKEY","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPharma \/ BIOKEY"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CASI Pharmaceuticals \/ Cleave Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CASI Pharmaceuticals \/ Cleave Therapeutics"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-668","moa":"IL4I1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CER-1236","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CERo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CERo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CERo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain 9","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CG001419","moa":"TRK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/B RxL","graph1":"Oncology","graph2":"IND Enabling","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CK0804","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-619","moa":"MICA\/MICB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Integral Molecular \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYTO NK-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCR-788","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncorus \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncorus \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Duet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"DUET-01","moa":"STAT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Duet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Estrella Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"EPIM-001","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpis Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpis Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpis Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-3490","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Escend Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ES-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Escend Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escend Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Escend Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"FG-3165","moa":"Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE705","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-300","moa":"PAP\/PSA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HFB200603","moa":"||BLTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HFB301001","moa":"OX40 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HPN601","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HPN601","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IAB56","moa":"Alpha-V beta 6 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Fox Chase Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Fox Chase Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Fox Chase Cancer Center"},{"orgOrder":0,"company":"RootPath","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"InfiniTIL","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RootPath","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RootPath \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RootPath \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialectic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"IND Enabling","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontier Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NEXI-003","moa":"CD3\/4","graph1":"Oncology","graph2":"IND Enabling","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-106","moa":"LAIR-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Cellectis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IOV-4001","moa":"TIL","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iovance Biotherapeutics \/ Cellectis","highestDevelopmentStatusID":"5","companyTruncated":"Iovance Biotherapeutics \/ Cellectis"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-2174","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JCXH-211","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immorna \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB-9558","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Tempus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN004","moa":"CDK12","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinnate Biopharma \/ Tempus","highestDevelopmentStatusID":"5","companyTruncated":"Kinnate Biopharma \/ Tempus"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KVA12.1","moa":"||VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KME-0584","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kurome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kurome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KO-2806","moa":"Farnesyl transferase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KROS-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KSQ-004EX","moa":"SOCS1 gene","graph1":"Oncology","graph2":"IND Enabling","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lomond Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lomond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lomond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MiNK-413","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"North Star Processing, LLC.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ North Star Processing, LLC.","highestDevelopmentStatusID":"5","companyTruncated":"Monopar Therapeutics \/ North Star Processing, LLC."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRTX1133","moa":"KRASG12D selective","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NPX887","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"Neogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXL-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuExcell therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/ Src-family kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OKI-219","moa":"PI3K Alpha H1047R","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Aurigene","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Aurigene"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTX-2101","moa":"c-Myc cell proliferation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ Pure Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Pure Biologics"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"P-CD19CD20-ALLO1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PLN-101095","moa":"Alpha 5-Beta 1\/alpha 5-beta 8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-321","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-202","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Fate Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GTB-3650","moa":"||CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Fate Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Fate Therapeutics"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GD2-SADA","moa":"GD2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-104","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"StemVacs-V","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALEXIS-PRO-1","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALEXIS-ISO-1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"IND Enabling","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ University College London","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ University College London"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-321","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lamassu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC262","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-2921","moa":"||CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-1505","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ST-00937","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resiquimod","moa":"TLR7\/8","graph1":"Oncology","graph2":"IND Enabling","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SURGE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SURGE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Decitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TEB-17231","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"280Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EDIT-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OM1","moa":"IL-15 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OncoMyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-2921","moa":"||CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-203","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EDIT-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TIDAL-01","moa":"T-lymphocyte","graph1":"Oncology","graph2":"IND Enabling","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Turnstone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-203-A0201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-204-A0201","moa":"MAGE-A1","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute of Harvard","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTX-810","moa":"MCL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trueline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Trueline Therapeutics \/ Broad Institute of Harvard","highestDevelopmentStatusID":"5","companyTruncated":"Trueline Therapeutics \/ Broad Institute of Harvard"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-D5","moa":"Bcl-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zalifrelimab","moa":"TLR7","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YL-17231","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"280Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Balamenib","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zumutor Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM14","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rondo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"RNDO-564","moa":"CD28\/Nectin-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rondo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rondo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rondo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Hookipa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Merger","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poolbeg Pharma \/ Hookipa Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Poolbeg Pharma \/ Hookipa Pharma"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ TCGX","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Brandon Capital","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ Brandon Capital"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Oxford Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"GSK","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptamer Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AST-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptamer Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptamer Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptamer Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVA3996","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AVA6103","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||dUTPase","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV6 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EXS74539","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"GammaDelta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDX012","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GammaDelta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GammaDelta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GammaDelta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"M300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mestag Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxilio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxilio \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Oxilio \/ Quotient Sciences"},{"orgOrder":0,"company":"Oxular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OXU-003","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NG-347","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Bluebird Bio","highestDevelopmentStatusID":"5","companyTruncated":"Akamis Bio \/ Bluebird Bio"}]

    Find FDA Investigational New Drug (IND) Submissions for Oncology

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Everest Medicines

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVM14

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Everest Gains FDA IND Clearance for Tumor-Associated Antigen Vaccine EVM14

                            Details : EVM14 is an off-the-shelf mRNA cancer vaccine targeting multiple tumor-associated antigens & is designed to treat various cancers, including non-small cell lung cancer and head and neck cancer.

                            Product Name : EVM14

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 23, 2025

                            Lead Product(s) : EVM14

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medicilon

                            China arrow
                            AAN
                            Not Confirmed

                            Medicilon

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oncotelic Accesses Rapid IND Development Platform Through Partnership with Medicilon

                            Details :

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 25, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rondo Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Rondo Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNDO-564

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rondo Presents CD28 x Nectin-4 Bispecific Antibody Data at ASCO GU

                            Details : RNDO-564 is a novel CD28 x Nectin-4 costimulatory bispecific antibody, currently beng investigated for advanced bladder cancer.

                            Product Name : RNDO-564

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 10, 2025

                            Lead Product(s) : RNDO-564

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Undisclosed

                            Country arrow
                            AAN
                            Not Confirmed

                            Undisclosed

                            Country arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOMA-989

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : MOMA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MOMA Announces Exclusive PARP1 Inhibitor License Agreement

                            Details :

                            Product Name : MOMA-989

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : MOMA-989

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : MOMA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Duality Biologics

                            China arrow
                            AAN
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1418

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Avenzo Therapeutics

                            Deal Size : $1,200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avenzo, DualityBio Sign License for EGFR/HER3 Antibody-Drug Conjugate

                            Details :

                            Product Name : AVZO-1418

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $50.0 million

                            January 07, 2025

                            Lead Product(s) : DB-1418

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Avenzo Therapeutics

                            Deal Size : $1,200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Innovent Biologics

                            China arrow
                            AAN
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBI3009

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,080.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Innovent, Roche Sign Exclusive License for DLL3 Antibody Drug Conjugate

                            Details :

                            Product Name : IBI3009

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $80.0 million

                            January 01, 2025

                            Lead Product(s) : IBI3009

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,080.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hervolution Therapeutics

                            Denmark arrow
                            AAN
                            Not Confirmed

                            Hervolution Therapeutics

                            Denmark arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPT-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Serum Institute of India

                            Deal Size : $11.7 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            HERVolution Secures $11.7M Series A for Cancer and Aging Disease Treatments

                            Details :

                            Product Name : IPT-001

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 19, 2024

                            Lead Product(s) : IPT-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Serum Institute of India

                            Deal Size : $11.7 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tasca Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Tasca Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAS 77168-63-9

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Regeneron Ventures

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tasca Therapeutics Launches with $52M Series A to Develop Oncology Inhibitors

                            Details :

                            Product Name : CP-383

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 10, 2024

                            Lead Product(s) : CAS 77168-63-9

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Regeneron Ventures

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Halda Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Halda Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLD-0915

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Deep Track Capital

                            Deal Size : $126.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies

                            Details : The proceeds from the financing will be used to advance two RIPTAC candidates into clinical trials, including HLD-0915, for patients with prostate cancer and breast cancer.

                            Product Name : HLD-0915

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 08, 2024

                            Lead Product(s) : HLD-0915

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Deep Track Capital

                            Deal Size : $126.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Anocca

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Anocca

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANOC-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anocca Submits VIDAR-1 Pancreatic Cancer Trial Application

                            Details : ANOC-001 is a T-cell receptor (TCR-T) cell therapy which targets mutant KRAS G12V, is being investigated in patients with advanced pancreatic cancer.

                            Product Name : ANOC-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 26, 2024

                            Lead Product(s) : ANOC-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth